Clinical Trials Browser

Phase 3 × HER2+ Breast Cancer × sintilimab × Clear all

NCT05429684 2022-06-23

Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer

Phase 3 Unknown

HER2+ Breast Cancer